Compared to mice in both PBS and Vac groups, mice bearing bilateral CT26 tumors receiving combination treatment of RFA and neoantigen vaccination (RFA+Vac group) displayed further inhibition of CT26 tumor growth on the right flank, proving the stronger antitumor efficacy of RFA+Vac combination treatment (Figure 5B). This evidence concerns the gene DDX53 and neoplasm.